Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, N-7491, Trondheim, Norway.
Cancer Clinic, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
BMC Cancer. 2018 Apr 3;18(1):381. doi: 10.1186/s12885-018-4164-5.
Knowledge about disease and treatment is necessary before patients can consent to treatment. One of the few established instruments for evaluating whether sufficient information has been provided, is the EORTC QLQ-INFO25 questionnaire which was developed to measure how patients perceive information. The aim of this study was to investigate whether cancer patients' level of knowledge about their disease and treatment was associated with their perception of and satisfaction with the information.
Breast cancer patients referred for adjuvant chemotherapy and prostate cancer patients referred for curative radiotherapy were included. Level of knowledge about their disease and treatment was measured using study-specific questionnaires. Patients' perception of and satisfaction with the received information was assessed using EORTC QLQ-INFO25. Assessments were done before the first consultation with an oncologist (T1), after the consultation (T2) and 8 weeks after start of treatment (T3).
Ninety eight patients were enrolled. Patients with higher education, daily Internet access and in paid employment had the highest baseline knowledge scores. The mean knowledge score increased significantly (T1: 16.4; T2: 20.8; T3: 21.3; p < 0.001.). During the same period, the patients reported on the INFO25 a significant, positive increase in how much information they had received, and that they were more satisfied with the information.
Patients' knowledge increased significantly during the study period, and they reported that they felt better informed and were more satisfied with the information, suggesting that EORTC QLQ-INFO25 might be used to evaluate cancer patients' level of knowledge about their disease and treatment.
ClinicalTrials.gov identifier: NCT01699672 . Date of registration: September 21, 2012.
患者在同意治疗之前必须了解疾病和治疗相关知识。评估是否已提供足够信息的少数既定工具之一是 EORTC QLQ-INFO25 问卷，该问卷旨在衡量患者对信息的感知。本研究旨在调查癌症患者对疾病和治疗的了解程度是否与其对信息的感知和满意度相关。
招募接受辅助化疗的乳腺癌患者和接受根治性放疗的前列腺癌患者。使用特定于研究的问卷测量患者对疾病和治疗的了解程度。使用 EORTC QLQ-INFO25 评估患者对所接受信息的感知和满意度。评估在首次咨询肿瘤医生前（T1）、咨询后（T2）和治疗开始后 8 周（T3）进行。
共纳入 98 例患者。接受更高教育、每日上网和有薪工作的患者具有最高的基线知识评分。知识评分呈显著增加（T1：16.4；T2：20.8；T3：21.3；p<0.001）。在同一时期，患者在 INFO25 上报告称，他们收到的信息量显著增加，并且对信息的满意度更高。
患者的知识在研究期间显著增加，他们报告说他们感觉得到了更好的信息告知，并且对信息的满意度更高，这表明 EORTC QLQ-INFO25 可能用于评估癌症患者对其疾病和治疗的了解程度。
ClinicalTrials.gov 标识符：NCT01699672。注册日期：2012 年 9 月 21 日。
